Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620875 | 0.91 | SLC18A3 (0.45) | SLC18A3TDP1CYP2D6ALDH1A1MEN1 | |
| SCHEMBL2618403 | 0.89 | SLC18A3 (0.41) | SLC18A3TDP1CYP2D6MEN1KMT2A | |
| SCHEMBL25540048 | 0.86 | SLC18A3 (0.41) | SLC18A3TDP1 | |
| SCHEMBL17706210 | 0.85 | SLC18A3 (0.39) | SLC18A3TDP1ALDH1A1KDM4EGAA | |
| SCHEMBL15217042 | 0.84 | SLC18A3 (0.38) | SLC18A3TDP1ALDH1A1KMT2AKDM4E | |
| SCHEMBL15217035 | 0.84 | SLC18A3 (0.38) | SLC18A3TDP1ALDH1A1KMT2AKDM4E | |
| SCHEMBL17376179 | 0.79 | SLC18A3 (0.41) | SLC18A3KMT2A | |
| SCHEMBL26619659 | 0.78 | ALDH1A1 (0.33) | SLC18A3ALDH1A1KMT2ALMNAKDM4E | |
| Hydrochloric Acid SCHEMBL19253935 | 0.78 | SLC18A3 (0.40) | SLC18A3KMT2ALMNA | |
| SCHEMBL27010158 | 0.77 | SLC18A3 (0.35) | SLC18A3TDP1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | SLC18A3 4310/4885TDP1 1177/4885CYP2D6 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.